A recent focus article in “Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology,” explores nanotechnology and its impact on medicine and biomedical research, as well as the need for informatics standards in Nanomedicine.  To read more about how Nanotechnology has the potential to make medicine more personalized, predictive, and preemptive, click here.

This new, five-year  grant will provide extended research support to allow Dr. Harper of Oregon State University to continue to develop one of the nation’s leading programs to test the safety of compounds created through nanotechnology. While Dr. Harper has many credits to her name and too many accomplishments to list here, we want to congratulate her on this latest achievement , and we look forward to continuing to work with Dr. Harper through the caBIG^®^ Nanotechnology Working Group. Please join us in congratulating Dr. Harper on this truly outstanding achievement and wish her continued success in her research endeavors.

Congratulations to Nathan Baker, leader of the caBIG^®^ Nanotechnology Working Group, and four other Pacific Northwest National Laboratory scientists who have been elected as fellows of the American Association for the Advancement of Science for their efforts to advance science or its applications. The Nanotechnology Working Group is helping to develop computational methods for the prediction of nanomaterial properties and the design of improved nanoparticles. To learn more about the AAAS fellowship award or the five recent selectees, please visit the latest PNNL publication:title=caBIG® Life Sciences Domain Analysis Model (LS DAM) v2.2.2 is Released

We are pleased to announce the release of the caBIG® Life Sciences Domain Analysis Model (LS DAM) v2.2.2. The LS DAM provides a shared view of semantics for the Life Sciences domain, which includes hypothesis-driven basic and pre-clinical research as well as discovery science.
The changes to the LS DAM in this release are described in the Release Summary and include

Changes to the Experiment Core for clearer alignment with the ISA-TAB standard and to address feedback from HL7 Clinical Genomics Work Group collaborators
Deletion of several classes determined not to be in scope of the model
Addition of an LS DAM Users Guide
Report and models from an LS DAM Ontological Representation Pilot project

For a complete list of modifications and additions to the LS DAM v 2.2.2, please see the Release Summary and Change List .  For an exemplar on how the Experiment Core of the LS DAM could be instantiated to support a sample scenario, please see the Experiment Implementation Guide.

The LS DAM v2.2.2 model is available in two formats:

An Enterprise Architect file may be downloaded LS DAM v 2.2.2 EA file
A web based view of the model is also available using Internet Explorer LS DAM v2.2.2 HTML

A recent focus article in “Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology,” explores nanotechnology and its impact on medicine and biomedical research, as well as the need for informatics standards in Nanomedicine.  To read more about how Nanotechnology has the potential to make medicine more personalized, predictive, and preemptive, click here.

This new, five-year  grant will provide extended research support to allow Dr. Harper of Oregon State University to continue to develop one of the nation’s leading programs to test the safety of compounds created through nanotechnology. While Dr. Harper has many credits to her name and too many accomplishments to list here, we want to congratulate her on this latest achievement , and we look forward to continuing to work with Dr. Harper through the caBIG^®^ Nanotechnology Working Group. Please join us in congratulating Dr. Harper on this truly outstanding achievement and wish her continued success in her research endeavors.